stockrow
Saturday 7 November 2026
Export PTIX’s income statement to Excel — free account
Atrinsic Inc.
PTIX Healthcare Biotechnology
- EPS
- +61.3%
- Free cash flow
- +46.1%
Quarter to June 2026, against a year earlier
0.54
0.09
−14.29%
Follow PTIX
Alert me
Atrinsic Inc. (PTIX) P/E ratio
As of 6 November 2026, Atrinsic Inc. (PTIX) trades at a P/E ratio of 0.2×. Over the past ten years it has ranged from 0.0× (March 2026) to 0.8× (April 2026); the current reading is higher than 96% of that period. That is below the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.8×
Ten-year median
0.0×
Current reading's percentile
96
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KPTI Karyopharm Therapeutics Inc. compare | n/m |
| BBLG Bone Biologics Corp. compare | n/m |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR compare | n/m |
| ARTL Artelo Biosciences, Inc. compare | n/m |
| MTNB Matinas Biopharma Holdings, Inc. compare | n/m |
| LABT Lakewood-Amedex Biotherapeutics Inc. compare | n/m |
| ELAB PMGC Holdings Inc. compare | n/m |
| PTIX Atrinsic Inc. | 0.2× |
| ABPO Abpro Holdings Inc. compare | 0.5× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)